NASDAQ:OCUL

Ocular Therapeutix Stock Forecast, Price & News

$15.89

-0.31 (-1.91 %)

(As of 04/13/2021 12:00 AM ET)

Add

Compare

Today's Range

$15.44

Now: $15.89▼

$16.20

50-Day Range

$15.82

MA: $18.31▼

$20.84

52-Week Range

$4.76

Now: $15.89▼

$24.30

Volume715,106 shs

Average Volume936,332 shs

Market Capitalization$1.21 billion

P/E RatioN/A

Dividend YieldN/A

Beta2.29

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:OCUL

Previous Symbol

CUSIPN/A

CIK1393434

Webwww.ocutx.com

Phone(781) 357-4000

Employees161

Year FoundedN/A

Debt

Debt-to-Equity Ratio8.86

Current Ratio3.58

Quick Ratio3.53

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$4.23 million

Price / Sales285.76

Cash FlowN/A

Price / Cash FlowN/A

Book Value($0.08) per share

Price / Book-198.63

Profitability

EPS (Most Recent Fiscal Year)($2.01)

Net Income$-86,370,000.00

Net Margins-780.19%

Return on Equity-14,065.71%

Return on Assets-81.81%

Miscellaneous

Outstanding Shares76,070,000

Market Cap$1.21 billion

Next Earnings Date5/14/2021 (Estimated)

OptionableOptionable

Headlines

Ocular Therapeutix (NASDAQ:OCUL) Shares Gap Down to $16.20
April 13, 2021 | americanbankingnews.com

-$0.20 Earnings Per Share Expected for Ocular Therapeutix, Inc. (NASDAQ:OCUL) This Quarter
April 11, 2021 | americanbankingnews.com

Ocular Therapeutix (NASDAQ:OCUL) Trading Up 7.9%
April 1, 2021 | americanbankingnews.com

Ocular Therapeutix (NASDAQ:OCUL) Stock Price Up 7.9%
April 1, 2021 | americanbankingnews.com

Can Ocular Therapeutix Reach Its Full Potential?
April 1, 2021 | finance.yahoo.com

$8.12 Million in Sales Expected for Ocular Therapeutix, Inc. (NASDAQ:OCUL) This Quarter
March 27, 2021 | americanbankingnews.com

First Week of OCUL May 21st Options Trading
March 19, 2021 | nasdaq.com

Ocular Therapeutix, Inc. (OCUL) CEO Antony Mattessich on Q4 2020 Results - Earnings Call Transcript
March 13, 2021 | seekingalpha.com

Ocular Therapeutix: Q4 Earnings Snapshot
March 11, 2021 | finance.yahoo.com

Ocular Therapeutix™ Reports Fourth Quarter and Year End 2020 Financial Results and Business Update
March 11, 2021 | finance.yahoo.com

Ocular Therapeutix (OCUL) Reports Q4 Loss, Lags Revenue Estimates
March 11, 2021 | finance.yahoo.com

OCUL December 17th Options Begin Trading
March 10, 2021 | nasdaq.com

Preview: Ocular Therapeutix's Earnings
March 10, 2021 | benzinga.com

Ocular Therapeutix™ Announces FDA Acceptance of Supplemental New Drug Application for DEXTENZA® (dexamethasone ophthalmic insert) for the Treatment of Ocular Itching ...
March 4, 2021 | businesswire.com

Will Ocular Therapeutix (OCUL) Report Negative Earnings Next Week? What You Should Know
March 4, 2021 | finance.yahoo.com

Ocular Therapeutix™ Announces FDA Acceptance of Supplemental New Drug Application for DEXTENZA® (dexamethasone ophthalmic insert) for the Treatment of Ocular Itching Associated with Allergic Conjunctivitis
March 4, 2021 | finance.yahoo.com

Conjunctivitis Market Size to Worth Around US$ 6.85 Bn by 2030
March 3, 2021 | ca.finance.yahoo.com

Ocular Therapeutix Shares Are Trading Higher As Company Starts Dosing In Mid-Stage Therapy Study For Dry Eye Disease
March 1, 2021 | markets.businessinsider.com

Ocular Therapeutix™ Announces First Patient Dosed in Phase 2 Clinical Trial of OTX-DED for the Short-Term Treatment of the Signs and Symptoms of Dry Eye Disease
March 1, 2021 | finance.yahoo.com

Ocular Therapeutix Inc hosts conference call for investors
February 28, 2021 | markets.businessinsider.com

See More Headlines

MarketRank^™

Overall MarketRank^™

1.59 out of 5 stars

Medical Sector

390th out of 2,019 stocks

Pharmaceutical Preparations Industry

181st out of 772 stocks

3.5 Analyst's Opinion

Consensus Rating
Ocular Therapeutix has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $24.80, Ocular Therapeutix has a forecasted upside of 56.1% from its current price of $15.89.
Amount of Analyst Coverage
Ocular Therapeutix has received no research coverage in the past 90 days.

3.0 Community Rank

Outperform Votes
Ocular Therapeutix has received 394 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Ocular Therapeutix has received 264 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Ocular Therapeutix has received 59.88% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Ocular Therapeutix and other stocks. Vote “Outperform” if you believe OCUL will outperform the S&P 500 over the long term. Vote “Underperform” if you believe OCUL will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Ocular Therapeutix does not currently pay a dividend.
Dividend Growth
Ocular Therapeutix does not have a long track record of dividend growth.

0.8 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Ocular Therapeutix insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 7.70% of the stock of Ocular Therapeutix is held by insiders.
Percentage Held by Institutions
52.45% of the stock of Ocular Therapeutix is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Ocular Therapeutix are expected to grow in the coming year, from ($0.97) to ($0.46) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Ocular Therapeutix is -8.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Ocular Therapeutix is -8.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

$15.89

-0.31 (-1.91 %)

(As of 04/13/2021 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive OCUL News and Ratings via Email

Sign-up to receive the latest news and ratings for OCUL and its competitors with MarketBeat's FREE daily newsletter.

Ocular Therapeutix (NASDAQ:OCUL) Frequently Asked Questions

Is Ocular Therapeutix a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ocular Therapeutix in the last twelve months. There are currently 1 hold rating, 2 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Ocular Therapeutix stock.
View analyst ratings for Ocular Therapeutix or view top-rated stocks.

What stocks does MarketBeat like better than Ocular Therapeutix?

Wall Street analysts have given Ocular Therapeutix a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Ocular Therapeutix wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Ocular Therapeutix's next earnings date?

Ocular Therapeutix is scheduled to release its next quarterly earnings announcement on Friday, May 14th 2021.
View our earnings forecast for Ocular Therapeutix.

How were Ocular Therapeutix's earnings last quarter?

Ocular Therapeutix, Inc. (NASDAQ:OCUL) announced its quarterly earnings data on Thursday, March, 11th. The biopharmaceutical company reported ($1.21) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.18) by $1.03. The biopharmaceutical company earned $7.35 million during the quarter, compared to analyst estimates of $7.73 million. Ocular Therapeutix had a negative net margin of 780.19% and a negative trailing twelve-month return on equity of 14,065.71%.
View Ocular Therapeutix's earnings history.

How has Ocular Therapeutix's stock price been impacted by Coronavirus (COVID-19)?

Ocular Therapeutix's stock was trading at $5.35 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, OCUL shares have increased by 197.0% and is now trading at $15.89.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for OCUL?

4 analysts have issued 1 year target prices for Ocular Therapeutix's shares. Their forecasts range from $14.00 to $30.00. On average, they anticipate Ocular Therapeutix's share price to reach $24.80 in the next twelve months. This suggests a possible upside of 56.1% from the stock's current price.
View analysts' price targets for Ocular Therapeutix or view top-rated stocks among Wall Street analysts.

Who are Ocular Therapeutix's key executives?

Ocular Therapeutix's management team includes the following people:

Antony Mattessich, President, Chief Executive Officer & Director
Patricia Kitchen, Chief Operating Officer
Donald Notman, Chief Financial & Accounting Officer
Peter Jarrett, Chief Scientific Officer
Michael H. Goldstein, Chief Medical Officer & Ophthalmology President

Who are some of Ocular Therapeutix's key competitors?

Some companies that are related to Ocular Therapeutix include Atea Pharmaceuticals (AVIR), Biohaven Pharmaceutical (BHVN), Hutchison China MediTech (HCM), Sage Therapeutics (SAGE), Arena Pharmaceuticals (ARNA), Hypera (HYPMY), Emergent BioSolutions (EBS), Turning Point Therapeutics (TPTX), Agios Pharmaceuticals (AGIO), I-Mab (IMAB), Legend Biotech (LEGN), Nektar Therapeutics (NKTR), Apellis Pharmaceuticals (APLS), PTC Therapeutics (PTCT) and ACADIA Pharmaceuticals (ACAD).
View all of OCUL's competitors.

What other stocks do shareholders of Ocular Therapeutix own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ocular Therapeutix investors own include Clearside Biomedical (CLSD), Northwest Biotherapeutics (NWBO), Novavax (NVAX), (CELG), Dynavax Technologies (DVAX), Omeros (OMER), Gilead Sciences (GILD), TG Therapeutics (TGTX), Inovio Pharmaceuticals (INO) and SCYNEXIS (SCYX).

What is Ocular Therapeutix's stock symbol?

Ocular Therapeutix trades on the NASDAQ under the ticker symbol "OCUL."

How do I buy shares of Ocular Therapeutix?

Shares of OCUL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ocular Therapeutix's stock price today?

One share of OCUL stock can currently be purchased for approximately $15.89.

How much money does Ocular Therapeutix make?

Ocular Therapeutix has a market capitalization of $1.21 billion and generates $4.23 million in revenue each year. The biopharmaceutical company earns $-86,370,000.00 in net income (profit) each year or ($2.01) on an earnings per share basis.

How many employees does Ocular Therapeutix have?

Ocular Therapeutix employs 161 workers across the globe.

What is Ocular Therapeutix's official website?

The official website for Ocular Therapeutix is www.ocutx.com.

Where are Ocular Therapeutix's headquarters?

Ocular Therapeutix is headquartered at 15 CROSBY DRIVE, BEDFORD MA, 01730.

How can I contact Ocular Therapeutix?

Ocular Therapeutix's mailing address is 15 CROSBY DRIVE, BEDFORD MA, 01730. The biopharmaceutical company can be reached via phone at (781) 357-4000 or via email at [email protected]

This page was last updated on 4/14/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here